Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg F Hoffmann

Showing results (31-40 of 381) with videos related to

Pageof 39
Sort By:
The Oncologist|March 30, 2016
Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional AnalysisClemens Stockklausner, Anette Lampert, Georg F Hoffmann, et al.
Orphanet Journal of Rare Diseases|May 14, 2016
Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug actThomas Lutz, Anette Lampert, Georg F Hoffmann, et al.
Orphanet Journal of Rare Diseases|April 22, 2015
Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug actKonstantin Mechler, William K Mountford, Georg F Hoffmann, et al.
Pediatric Neurology|October 1, 2015
Recurrent Stroke-Like Episodes in FBXL4-Associated Early-Onset Mitochondrial EncephalomyopathyDarius Ebrahimi-Fakhari, Angelika Seitz, Stefan Kölker, et al.
Pediatric Research|October 30, 2013
Emerging role of autophagy in pediatric neurodegenerative and neurometabolic diseasesDarius Ebrahimi-Fakhari, Lara Wahlster, Georg F Hoffmann, et al.
Journal of Inherited Metabolic Disease|September 20, 2012
Screening for congenital disorders of glycosylation in the first weeks of lifeChristian Thiel, Dorothea Meßner-Schmitt, Georg F Hoffmann, et al.
International Journal of Methods in Psychiatric Research|November 19, 2016
Defining the hidden evidence in autism research. Forty per cent of rigorously designed clinical trials remain unpublished - a cross-sectional analysisKonstantin Mechler, Georg F Hoffmann, Ralf W Dittmann, et al.
Plos One|August 25, 2016
Thirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional AnalysisJan Henje Döring, Anette Lampert, Georg F Hoffmann, et al.
Annals of African Medicine|October 25, 2017
Iron and vitamin D levels among autism spectrum disorders childrenAbdulbari Bener, Azhar O Khattab, Dinesh Bhugra, et al.
Molecular Genetics and Metabolism|February 5, 2013
Pitfalls in phenylalanine loading test in the diagnosis of dopa-responsive dystoniaThomas Opladen, Georg F Hoffmann, Andrea A Kühn, et al.
Pageof 39

Showing results (31-40 of 381) with videos related to

Sort By:
Pageof 39
The Oncologist|March 30, 2016
Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional AnalysisClemens Stockklausner, Anette Lampert, Georg F Hoffmann, et al.
Orphanet Journal of Rare Diseases|May 14, 2016
Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug actThomas Lutz, Anette Lampert, Georg F Hoffmann, et al.
Orphanet Journal of Rare Diseases|April 22, 2015
Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug actKonstantin Mechler, William K Mountford, Georg F Hoffmann, et al.
Pediatric Neurology|October 1, 2015
Recurrent Stroke-Like Episodes in FBXL4-Associated Early-Onset Mitochondrial EncephalomyopathyDarius Ebrahimi-Fakhari, Angelika Seitz, Stefan Kölker, et al.
Pediatric Research|October 30, 2013
Emerging role of autophagy in pediatric neurodegenerative and neurometabolic diseasesDarius Ebrahimi-Fakhari, Lara Wahlster, Georg F Hoffmann, et al.
Journal of Inherited Metabolic Disease|September 20, 2012
Screening for congenital disorders of glycosylation in the first weeks of lifeChristian Thiel, Dorothea Meßner-Schmitt, Georg F Hoffmann, et al.
International Journal of Methods in Psychiatric Research|November 19, 2016
Defining the hidden evidence in autism research. Forty per cent of rigorously designed clinical trials remain unpublished - a cross-sectional analysisKonstantin Mechler, Georg F Hoffmann, Ralf W Dittmann, et al.
Plos One|August 25, 2016
Thirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional AnalysisJan Henje Döring, Anette Lampert, Georg F Hoffmann, et al.
Annals of African Medicine|October 25, 2017
Iron and vitamin D levels among autism spectrum disorders childrenAbdulbari Bener, Azhar O Khattab, Dinesh Bhugra, et al.
Molecular Genetics and Metabolism|February 5, 2013
Pitfalls in phenylalanine loading test in the diagnosis of dopa-responsive dystoniaThomas Opladen, Georg F Hoffmann, Andrea A Kühn, et al.
Pageof 39